Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 8,271 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Risk Clear all

Conditions: Hypersensitivity, Immediate, Hypersensitivity, Delayed, Hypersensitivity Response
Interventions: Direct oral penicillin challenge, Standard of care; Other
Lead sponsor: Austin Health; Government
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Durham, North Carolina • Nashville, Tennessee

Conditions: Pneumonia, Ventilator-Associated, Pneumonia, Bacterial, Pneumonia, Hospital-Acquired
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 7,530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 12 more

Conditions: Autism Spectrum Disorder, Attention Deficit/Hyperactivity Disorder, Developmental Delay
Interventions: Not listed
Lead sponsor: Thomas W. Frazier, Ph.D; Other
Eligibility: 1 Year to 12 Years
Enrollment: 456 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Not listed
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 28 more

Conditions: High Risk for Developing Breast Cancer
Interventions: Nonlinear Aerobic Training, Height, Weight, BMI measure, Blood draw, Cardiopulmonary exercise test; Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
Interventions: bleomycin sulfate, filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, autologous bone marrow transplantation, bone marrow ablation with stem cell support, conventional surgery, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 12 Years and older · Male only
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2006
U.S. locations: 149
States / cities: Anniston, Alabama • Tucson, Arizona • Little Rock, Arkansas + 105 more

Conditions: Cancer
Interventions: Aspiration Thrombectomy; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Aspiration
Interventions: Combined speech therapy tools, measures of swallowing function; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Body Image, Eating Disorder Symptom
Interventions: EVERYbody Project; Behavioral
Lead sponsor: Western Washington University; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Bellingham, Washington

Conditions: Obesity
Interventions: Education Intervention; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 3 Years to 13 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Acute Kidney Injury
Interventions: Not listed
Lead sponsor: Astute Medical, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 890 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 19
States / cities: Phoenix, Arizona • San Diego, California • Washington D.C., District of Columbia + 16 more

Conditions: Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory High Risk Myelodysplastic Syndrome
Interventions: Cladribine, Cytarabine, Idarubicin, Quizartinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obesity, Metabolic Disease, Eating Behavior, Adiposity, Sleep, Physical Activity
Interventions: Not listed
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 24 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Lymphoma
Interventions: rituximab, Bendamustin, bortezomib, lenalidomide; Biological · Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 227
States / cities: Greenbrae, California • Salinas, California • Stanford, California + 158 more

Conditions: Socio-emotional Well-being, Psychological Well-Being
Interventions: Mentoring Intervention Delivery; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 12 Years to 16 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alzheimer Disease, Mild Alzheimer Disease, MCI With Increased Risk for Alzheimer Disease, Cognitive Impairment, Mild
Interventions: Siponimod, Placebo; Drug
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 50 Years to 85 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Lymphoma
Interventions: carboplatin, etoposide, ifosfamide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 72 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: SOLVE-IT; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 24 Years · Male only
Enrollment: 2,020 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Solid Tumor, Adult
Interventions: ASV® AGEN2017 + QS-21 Stimulon® adjuvant; Biological
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Oral Cavity Carcinoma, Oral Intraepithelial Neoplasia
Interventions: Laboratory Biomarker Analysis, Patient Observation, Pembrolizumab; Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Stroke, Ischemic
Interventions: Transitional Care Program; Other
Lead sponsor: Syntrillo, Inc; Other
Eligibility: 30 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Winchester, Virginia

Conditions: Myelodysplastic Syndromes
Interventions: Elritercept, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 25
States / cities: Duarte, California • Glendale, California • La Jolla, California + 21 more

Conditions: Multiple Myeloma
Interventions: Pomalidomide; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Relapsed/Refractory Multiple Myeloma (RRMM)
Interventions: Linvoseltamab, Tocilizumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Los Angeles, California • St. Petersburg, Florida • Baton Rouge, Louisiana + 4 more

Search by objective public record fields.

The Use of Penicillin Allergy Clinical Decision Rule to Enable Direct Oral Penicillin Challenge

CTTI Risk Factors for HABP/VABP Study

Evaluating the Validity of a Genetic Risk Assessment Tool in Identifying Autism Spectrum Disorder

PREVENT ALL ALS Study

Dose-Response of Aerobic Training in Women at High-Risk for Development of Breast Cancer

Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors

A Prospective Single Center, Single Arm, Single-institution Registry That Aims to Assess the Safety and Quality of Life Benefits of Computer-assisted Vacuum Thrombectomy (CAVT) in the Treatment of Cancer Patients With Intermediate Risk Pulmonary Embolism (PE)

Correlation of Phonation With Deglutition and Aspiration Risk in the ICU Patients - an Exploratory Study

Pilot Evaluation of the EVERYbody Project

Parent Perceptions of Weight Status: Impact of a Pilot Intervention

Evaluation of Novel Biomarkers From Acutely Ill Patients at Risk for Acute Kidney Injury

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Eating Frequency and Visceral Adipose Tissue, Body Fat, and Obesity Risk in Hispanic College Freshmen

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

Bridging the Divide: A Pioneering Culturally-Specific Mentoring Intervention to Increase Support for At-Risk Youth

Repurposing Siponimod for Alzheimer's Disease

Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma

The SOLVE-IT National Randomized Trial

Phase 1a Study to Evaluate Immunogenicity of ASV®

Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia

Transitional Care Program to Improve Risk Factors in Stroke Survivors

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma

Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)